Intercontinental Exchange Inc (ICE) Stock News

Law firm Robbins Geller Rudman & Dowd LLP announced class action lawsuits against GRAIL, Inc. (NASDAQ: GRAL) for allegedly making false statements about its NHS-Galleri cancer screening trial. GRAIL failed to achieve the primary endpoint of reducing Stage III-IV cancers, causing the stock to fall over 50% on February 19, 2026. The firm is seeking lead plaintiffs from investors who purchased GRAL stock between May 13, 2025 and February 19, 2026. Similar lawsuits were also filed against Commvault Systems, Inc. and PicS N.V.

The article compares NICE and Twilio as investment options for 2026. NICE is recommended as the better choice due to its established profitability (20.8% net margin), lower valuation (Forward P/E of 9.0x), and proven cloud momentum across 150+ countries. While Twilio shows impressive headline revenue growth of 14%, the article argues this is inflated by carrier pass-through fees that don't contribute to gross profit, with underlying organic growth being more modest. NICE's steady execution and AI-embedded enterprise solutions are positioned as more attractive than Twilio's still-developing voice AI story.

Girard Sharp LLP is investigating potential securities claims on behalf of former Blue Owl Technology Finance Corp. II investors who received shares in the merger with Blue Owl Technology (NYSE: OTF) on March 24, 2025. Since the NYSE listing on June 13, 2025, Blue Owl Technology's share price has declined over 30%, with the investigation focusing on potential undisclosed issues with the fund's investment portfolios.

Video appears to show events around alleged ICE shooting in Maine  Reuters

A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringement letter from Revolution Medicines and adverse Phase I clinical data including a patient death, Erasca's stock fell approximately 59% in total.

A securities class action lawsuit has been filed against Nano-X Imaging (NNOX) alleging the company made false statements about operational efficiency and product demand while concealing poor manufacturing alignment, increased cash burn, and restructuring risks. The lawsuit covers investors who purchased securities between March 31, 2025 and April 17, 2026. The deadline to seek lead plaintiff status is August 11, 2026. The action was triggered after Nano-X reported a $33.4 million net loss in Q4 2025, including a $17.5 million impairment charge related to restructuring at its Korean facility, causing the stock to fall 24.39%.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

A securities class action lawsuit has been filed against Peabody Energy Corporation for allegedly making false and misleading statements about its Centurion mine operations. The company provided overly positive guidance while concealing material operational challenges. Stock price declined significantly following corrective disclosures on March 30, 2026 (down 9.7%) and May 5, 2026 (down 5.7%) when the company revealed commissioning delays and reduced output expectations. The deadline to seek lead plaintiff status is August 24, 2026.

A federal securities class action has been filed against Lucid Group alleging that the company and its executives made false and misleading statements by concealing a supplier quality issue that significantly disrupted Lucid Gravity deliveries and overstating manufacturing capabilities. The lawsuit covers investors who purchased LCID stock between February 25, 2026 and April 13, 2026. The deadline to seek lead plaintiff appointment is July 28, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

Rosen Law Firm reminds investors who purchased Lucid Group securities between February 25, 2026 and April 13, 2026 of the July 28, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Lucid made false statements regarding supplier quality issues that disrupted Lucid Gravity deliveries and overstated manufacturing capabilities, resulting in material negative impact on the company's business and financial results.

Moore Law PLLC is investigating ICON plc (NASDAQ: ICLC) following the company's announcement of an internal audit committee investigation into accounting practices and controls initiated in October 2025. ICON's stock price dropped significantly on February 12, 2026, when the company disclosed the investigation and delayed its earnings release to April 30, 2026.

Moore Law PLLC is investigating Veritone, Inc. for allegedly making false statements regarding revenue recording and misclassification of costs, resulting in overstated revenue and assets. The company disclosed on April 14, 2026, that previously issued financial statements should no longer be relied upon due to significant revenue overstatement and net loss understatement errors. Veritone's stock fell 29.5% following the March 26 announcement of accounting determination issues.

Moore Law PLLC is investigating Super Micro Computer, Inc. (SMCI) for potential securities fraud following multiple disclosures in August-September 2024. The company revealed margin pressures on August 6, faced Hindenburg Research allegations of fraudulent revenue recognition and accounting irregularities on August 27, announced delayed 10-K filing on August 28, and faced a DOJ investigation announcement on September 26. These events triggered significant stock price declines totaling over 34% across the disclosure period.

Law firm Girard Sharp LLP is investigating potential securities claims on behalf of former HanesBrands investors who received Gildan shares in the December 2025 acquisition. Gildan's stock price has declined significantly since the merger closed, prompting the investigation into potential securities violations.

ICE agent fatally shoots Mexican motorist in Texas during vehicle stop, agency says  Reuters

Rosen Law Firm reminds Lucid Group, Inc. investors who purchased securities between February 25, 2026 and April 13, 2026 of the July 28, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Lucid made false statements regarding supplier quality issues that disrupted Gravity deliveries and overstated manufacturing capabilities, causing material negative impact on the company's business and financial results.

Law firm Girard Sharp LLP is investigating potential securities claims on behalf of former Berry Global investors who received Amcor shares in the April 2025 merger. Amcor's stock price has declined significantly since the merger closed, prompting the investigation into possible securities violations.

Rosen Law Firm has filed securities class action lawsuits against Veritone, Insulet Corporation, and Genius Group Limited. The primary case involves Veritone, which allegedly made false statements about its financial performance, including inaccurate revenue recording, misclassification of costs, and deficient internal controls. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 20, 2026 lead plaintiff deadline.

ADMA Biologics faces a federal securities class action lawsuit alleging the company made false statements about its financial performance through channel stuffing schemes and undisclosed related party transactions. An investigative report revealed ADMA artificially inflated 2025 revenue growth from -3% to +20% by inducing distributors to overstock products with rebates and extended payment terms. The stock declined 29% following the report's publication on March 24, 2026. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with a deadline of August 10, 2026 to seek lead plaintiff status.

A federal securities class action has been filed against FS KKR Capital Corp. (FSK) alleging that the company and its executives made false and misleading statements regarding portfolio restructuring effectiveness, investment valuations, and dividend sustainability. The lawsuit covers investors who purchased FSK stock between May 8, 2024 and February 25, 2026. The deadline to seek lead plaintiff appointment is July 3, 2026.

A federal securities class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company and its executives made false and misleading statements about the Fabric Genomics acquisition and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555 million to $475-490 million, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition purchased for $36.5 million one year prior. The stock fell over 49% on the news. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with a deadline of August 3, 2026 to seek lead plaintiff appointment.

A securities class action lawsuit has been filed against Peabody Energy Corporation for allegedly making false and misleading statements about its Centurion mine operations. The company provided overly positive guidance while concealing material operational challenges. Stock price declined significantly following corrective disclosures on March 30, 2026 (9.7% drop) and May 5, 2026 (5.7% drop) when the company revealed commissioning delays and reduced production guidance. The deadline to seek lead plaintiff status is August 24, 2026.

A federal securities class action has been filed against AeroVironment, Inc. alleging that the company and its executives made false and misleading statements by concealing imminent competition for its SCAR program contracts and overstating business prospects. Investors who purchased AVAV stock between June 25, 2025 and March 10, 2026 may be eligible to participate. The deadline to seek lead plaintiff appointment is July 27, 2026.

A federal securities class action has been filed against Roblox Corporation alleging that executives made false and misleading statements about the company's organic growth potential. The lawsuit claims Roblox concealed that its age verification rollout would significantly slow growth rates and reduce engagement. On April 30, 2026, when Roblox revealed the true impact and slashed guidance, its stock plummeted 18.33% in a single day. Investors who purchased RBLX securities between October 30, 2025 and April 30, 2026 may be eligible to participate, with the lead plaintiff deadline set for August 7, 2026.

A securities class action lawsuit has been filed against Nano-X Imaging (NNOX) alleging the company made false statements about operational efficiency and product demand while concealing poor manufacturing alignment, increased cash burn, and restructuring risks. The lawsuit covers purchases between March 31, 2025 and April 17, 2026. Investors have until August 11, 2026 to seek lead plaintiff status. The action follows Nano-X's April 2026 announcement of a $33.4 million quarterly loss including a $17.5 million asset impairment charge, which triggered a 24.39% stock price decline.

Faruqi & Faruqi, LLP is investigating a federal securities class action against Lucid Group for allegedly making false and misleading statements about supplier quality issues that disrupted Lucid Gravity deliveries and overstating manufacturing capabilities. The lawsuit covers investors who purchased LCID stock between February 25, 2026 and April 13, 2026. The deadline to seek lead plaintiff appointment is July 28, 2026.

A securities class action lawsuit has been filed against Sportradar Group AG alleging the company made false statements about its compliance practices and knowingly worked with black-market gambling operators while claiming strict regulatory compliance. Investors who purchased SRAD securities between November 7, 2024 and April 21, 2026 have until July 17, 2026 to seek lead plaintiff status.